Frontrunners in Bispecific Antibodies: Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

The article focuses on Affimed N.V.'s utilization of the ROCK platform to develop customized innate cell engager molecules, including AFM13, AFM24, and AFM28, for cancer treatment. Topics discussed include Affimed's strategic alliances, Merus' advancements in bispecific antibodies, and challenges and future opportunities in bispecific antibody production and clinical application.